These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer.
    Author: Yap HY, Salem P, Hortobagyi GN, Bodey GP, Buzdar AU, Tashima CK, Blumenschein GR.
    Journal: Cancer Treat Rep; 1978 Mar; 62(3):405-8. PubMed ID: 348308.
    Abstract:
    Twenty-six patients with metastatic breast cancer received cis-dichlorodiammineplatinum(II) either as a single dose of 100 mg/m2 iv every 3--4 weeks or as a continuous 5-day infusion of 20 mg/m2/day at 4-week intervals. Fourteen patients were treated with the single-dose schedule and 12 patients were treated with the continuous 5-day infusion. No significant response was observed with either dose schedule. Aside from a reduction in the frequency and severity of gastrointestinal toxicity with the continuous 5-day infusion, no real difference was seen with regard to renal and hematologic toxicity with either dose schedule.
    [Abstract] [Full Text] [Related] [New Search]